Alaunos Therapeutics Inc
NASDAQ:TCRT
Operating Margin
Alaunos Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Alaunos Therapeutics Inc
NASDAQ:TCRT
|
6.4m USD |
-41 630%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
334.3B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
158.5B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
134.7B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.2B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
124.6B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
58.7B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.8B USD |
-5%
|
Alaunos Therapeutics Inc
Glance View
Alaunos Therapeutics, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. The company went IPO on 2004-08-20. The firm is focused on discovering, developing, and commercializing immuno-oncology platforms. The firm is engaged in developing technologies that utilize the immune system by employing innovative cell engineering to deliver cell therapies for the treatment of multiple cancer types. The company is focused on developing T-cell receptor (TCR), T cell therapies to target neoantigens in solid tumors (TCR-T). The firm's platform Sleeping Beauty is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that engineers T cells outside of the body for subsequent infusion. The company targets tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR, which are prevalent in gastrointestinal, lung, and gynecological cancers. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Alaunos Therapeutics Inc's most recent financial statements, the company has Operating Margin of -41 630%.
You don't have any saved screeners yet